Breaking Finance News

Cantor Fitzgerald downgraded Alcobra Pharma (NASDAQ:ADHD) from Buy to Hold in a statement released earlier today.

Cantor Fitzgerald has downgraded Alcobra Pharma (NASDAQ:ADHD) from Buy to Hold in a report released on 09/29/2016.

Previously on 9/12/2016, WBB Securities reported about Alcobra Pharma (NASDAQ:ADHD) bumped down the target price from $5.00 to $4.00. At the time, this indicated a possible downside of -0.17%.

Only yesterday Alcobra Pharma (NASDAQ:ADHD) traded -53.64% lower at $4.62. Alcobra Pharma’s 50-day moving average is $4.83 and its 200-day moving average is $4.53. The last stock close price is up -52.77% relative to the two hundred day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the date range. Trading volume was up over the average, with 1,624,270 shares of ADHD changing hands over the typical 92,709

Performance Chart

Alcobra Pharma (NASDAQ:ADHD)

Alcobra Pharma has a 52 week low of $2.00 and a 52 week high of $8.78 ADHD’s total market value is presently $0.

A total of 7 analysts have released a research note on ADHD. Three brokers rating the stock a strong buy, 3 brokerages rating the stock a buy, 0 analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally 0 analysts rating the company a sell with a 12-month price target of $12.71.

General Information About Alcobra Pharma (NASDAQ:ADHD)

Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse. MG01CI product has completed phase two studies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.